| Bioactivity | Indobufen is a platelet aggregation inhibitor. Indobufen is a reversible platelet cyclooxygenase (Cox) activity inhibitor. Indobufen suppresses thromboxane A2 (TxA2) synthesis. Indobufen down-regulates tissue factor (TF) in monocytes[1]. | |||||||||
| Invitro | Indobufen does not affect both Cox-1 and Cox-2 protein, whereas Indobufen reduces TxB2 levels. Indobufen inhibits TxA2 but not PGE2 synthesis in LPS-stimulated monocytes. Indobufen reduces the extent of ERK1/2 phosphorylation, whereas the levels of phosphorylated p38 are unaltered[1]. | |||||||||
| Name | Indobufen | |||||||||
| CAS | 63610-08-2 | |||||||||
| Formula | C18H17NO3 | |||||||||
| Molar Mass | 295.33 | |||||||||
| Appearance | Solid | |||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | |||||||||
| Storage |
|
|||||||||
| Reference | [1]. Eligini S, et al. Indobufen inhibits tissue factor in human monocytes through a thromboxane-mediated mechanism. Cardiovasc Res. 2006 Jan;69(1):218-26. |